CardioSource WorldNews | Page 7

LIVE COURSES 2016 January 16–20 June 04–07 June 17–18 The Westin Snowmass Resort Snowmass, CO Mexico City, Mexico The Westin Houston Memorial City Houston, TX Cardiovascular Conference at Snowmass: Contemporary Approaches to Clinical Care World Heart Federation | World Congress of Cardiology & Cardiovascular Health 2016 Care of the Athletic Heart: Translating Clinical Science into Practice Strategies B:7.875 in February 06–07 T:7.5 in S:7 in 2016 Women in Cardiology (WIC) Section Leadership Workshop Add Corlanor ® to maximally tolerated doses of beta-blockers and help give Heart House Washington, DC appropriate patients with heart rate ≥ 70 bpm and stable, symptomatic chronic HF... MORE HOME. LESS HOSPITAL. February 15–19 38th Annual Cardiology at Big Sky Huntley Lodge Big Sky, MT February 18–20 Learn how you can DO MORE with Corlanor® to reduce the risk of hospitalization for worsening heart failure (HF) 2016 Cardiovascular Summit: Solutions for Thriving in a Time of Change 1 CorlanorHCP.com The Cosmopolitan of Las Vegas Las Vegas, NV April 02–04 ACC.16 65th Annual Scientific Session & Expo McCormick Center Chicago, IL May 05–07 Recent Advances in Clinical Nuclear Cardiology and Cardiac CT: State of the Art Updates and 101 EvidenceBased Case Reviews Capital Hilton Washington, DC Review Live Courses and Meetings at ACC.org by scanning the code. Indication Corlanor® (ivabradine) is indicated to reduce the risk of hospitalization for worsening heart failure in patients with stable, symptomatic chronic heart failure with left ventricular ejection fraction ≤ 35%, who are in sinus rhythm with resting heart rate ≥ 70 beats per minute and either are on maximally tolerated doses of beta-blockers or have a contraindication to beta-blocker use. Important Safety Information Contraindications: Corlanor® is contraindicated in patients with acute decompensated heart failure, blood pressure < 90/50 mmHg, sick sinus syndrome, sinoatrial block, 3rd degree atrioventricular block (unless a functioning demand pacemaker is present), a resting heart rate < 60 bpm prior to treatment, severe hepatic impairment, pacemaker dependence (heart rate maintained exclusively by the pacemaker), and concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors. Fetal Toxicity: Corlanor® may cause fetal toxicity when administered to a pregnant woman based on embryo-fetal toxicity and cardiac teratogenic effects observed in animal studies. Advise females to use effective contraception when taking Corlanor®. Atrial Fibrillation: Corlanor® increases the risk of atrial fibrillation. The rate of atrial fibrillation in patients treated with Corlanor® compared to placebo was 5% vs. 3.9% per patient-year, respectively. Regularly monitor cardiac rhythm. Discontinue Corlanor® if atrial fibrillation develops. © 2015 Amgen Inc. All rights reserved. Not for reproduction. USA-998-115485 11-15 Bradycardia and Conduction Disturbances: Bradycardia, sinus arrest and heart block have occurred with Corlanor®. The rate of bradycardia in patients treated with Corlanor® compared to placebo was 6% (2.7% symptomatic; 3.4% asymptomatic) vs. 1.3% per patient-year, respectively. Risk factors for bradycardia include sinus node dysfunction, conduction defects, ventricular dyssynchrony, and use of other negative chronotropes. Concurrent use of verapamil or diltiazem also increases Corlanor® exposure, contributes to heart rate lowering, and should be avoided. Avoid use of Corlanor® in patients with 2nd degree atrioventricular block unless a functioning demand pacemaker is present. Adverse Reactions: The most common adverse drug reactions reported at least 1% more frequently with Corlanor® than placebo and that occurred in more than 1% of patients treated with Corlanor® were bradycardia (10% vs. 2.2%), hypertension or increased blood pressure (8.9% vs. 7.8%), atrial fibrillation (8.3% vs. 6.6%), and luminous phenomena (phosphenes) or visual brightness (2.8% vs. 0.5%). Please see Brief Summary of full Prescribing Information on adjacent page. BPM = beats per minute; HF = heart failure. Reference: 1. Corlanor® (ivabradine) Prescribing Information, Amgen.